Rocco Barbieri

Mr. Barbieri brings a combination of financial, business acumen and experience to his position on Telsource’s board of directors. In this role, as in other positions throughout his career, he couples an in-depth understanding of operational, financial analysis and management skills to bring a new level of depth and experience to the management team.

Mr. Barbieri's broad-based understanding of manufacturing operations coupled with his focus on cost control has been instrumental to the Company.

From 1973 to 1988 Mr. Barbieri held various positions with General Felt Industries and its parent Company. These positions were Vice President of Finance, Executive Vice President and President of General Felt. Additionally he held the positions of President of the parent Company Twenty-One Holdings and was a member of the Board of Directors.

In 1988, in a leveraged buyout with Merrill Lynch, he purchased General Felt Industries and held the position of President, Chief Executive Officer and Chairman of the Board. In 1993, General Felt Industries was sold to Foamex International and Mr. Barbieri retained his position as President and Chief Executive Officer and was appointed Senior Vice President of Foamex and a member of the Board of Directors.

Mr. Barbieri is a CPA and holds a B.S. degree from Villanova University.

Stephen McLean

Mr. McLean is a Managing Director of Arena Capital Partners, LLC, which manages a private equity fund that invests in middle-market manufacturing and service companies.

Previously, Mr. McLean was a founding partner of Merrill Lynch Capital Partners, Inc. (and its successor, Stonington Partners), a leader in the development of the Leveraged Buyout Industry. Over the last 25 years, Mr. McLean has helped to raise and manage aggregate private equity funds of $2.8 billion invested in a variety of companies including Borg Warner Corporation, First USA, Ann Taylor, Jack Eckerd Drug, Pathmark Stores, Denny’s Restaurants, Simmons Mattress, and Education Management Corporation.

Mr. McLean is also an active personal investor/board member of private companies in the healthcare and information services industries. In Healthcare, companies in which he has been a private investor include Agencourt Bioscience Corporation (nucleic acid reagents and genomic sequencing) and Agencourt Personal Genomics (polony based sequencing instruments), Packard Bioscience (analytical instruments), Cure DM (diabetes biotech), RS Medical Corporation (orthopedic devices) and Obagi Medical (dermatological products). Information service companies in which he has been a private investor include EduNeering Corporation (pharmaceutical/life science information services), CentriHealth (Individualized Health Records) and CBeyond Inc. (IP based communication services for small to medium sized businesses).

Mr. McLean is the Chairman of the International Biomedical Research Alliance, (“IBRA”). IBRA is a private sector foundation formed to support an advanced biomedical PhD program, the NIH/Oxford/Cambridge Scholars Program, (the “Program”). The Program was established in 2000 by Dr. Harold Varmus and Dr. Michael Lenardo of NIH to accelerate the training of American and British biomedical PhD’s. It is the only academic program in the world to be an affiliate organization of the Rhodes scholarship. In addition to providing financial support to Scholars enrolled in the Program, IBRA actively provides strategic guidance to NIH Program administrators regarding student recruitment, Program management, private sector priorities and Scholar placement.

Mr. McLean holds an M.B.A. with distinction from the Wharton School (1980) and a B.S. in Economics summa cum laude from the University of Pennsylvania (1979). He is an occasional lecturer at Wharton for the Wharton Department of Business Ethics.